BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32222024)

  • 1. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.
    Li J; Qin X; Wu R; Wan L; Zhang L; Liu R
    J Cell Mol Med; 2020 May; 24(9):5152-5161. PubMed ID: 32222024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA highly upregulated in liver cancer promotes the progression of hepatocellular carcinoma and attenuates the chemosensitivity of oxaliplatin by regulating miR-383-5p/vesicle-associated membrane protein-2 axis.
    Li P; Li Y; Ma L
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00815. PubMed ID: 34223709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway.
    Huang G; Liang M; Liu H; Huang J; Li P; Wang C; Zhang Y; Lin Y; Jiang X
    Cell Death Dis; 2020 Dec; 11(12):1065. PubMed ID: 33311442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F; Yin LX
    Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CircRNA-104718 acts as competing endogenous RNA and promotes hepatocellular carcinoma progression through microRNA-218-5p/TXNDC5 signaling pathway.
    Yu J; Yang M; Zhou B; Luo J; Zhang Z; Zhang W; Yan Z
    Clin Sci (Lond); 2019 Jul; 133(13):1487-1503. PubMed ID: 31278132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma.
    Qiu L; Huang Y; Li Z; Dong X; Chen G; Xu H; Zeng Y; Cai Z; Liu X; Liu J
    Mol Oncol; 2019 Feb; 13(2):441-455. PubMed ID: 30537115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression.
    Liu Z; Yu Y; Huang Z; Kong Y; Hu X; Xiao W; Quan J; Fan X
    Cell Death Dis; 2019 Nov; 10(12):900. PubMed ID: 31776329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421.
    Wang W; Li Y; Li X; Liu B; Han S; Li X; Zhang B; Li J; Sun S
    Biomed Pharmacother; 2020 Jan; 121():109517. PubMed ID: 31698267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
    Que KT; Zhou Y; You Y; Zhang Z; Zhao XP; Gong JP; Liu ZJ
    J Exp Clin Cancer Res; 2018 Nov; 37(1):268. PubMed ID: 30400960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA circHIAT1 inhibits cell growth in hepatocellular carcinoma by regulating miR-3171/PTEN axis.
    Wang Z; Zhao Y; Wang Y; Jin C
    Biomed Pharmacother; 2019 Aug; 116():108932. PubMed ID: 31108351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circular RNA hsa_circRNA_103809 promoted hepatocellular carcinoma development by regulating miR-377-3p/FGFR1/ERK axis.
    Zhan W; Liao X; Chen Z; Li L; Tian T; Yu L; Wang W; Hu Q
    J Cell Physiol; 2020 Feb; 235(2):1733-1745. PubMed ID: 31317555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N
    Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
    Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.
    Huang H; Chen J; Ding CM; Jin X; Jia ZM; Peng J
    J Cell Mol Med; 2018 Jun; 22(6):3238-3245. PubMed ID: 29602203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
    Yu J; Xu QG; Wang ZG; Yang Y; Zhang L; Ma JZ; Sun SH; Yang F; Zhou WP
    J Hepatol; 2018 Jun; 68(6):1214-1227. PubMed ID: 29378234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of circular RNA circ_0008450 predicts dismal prognosis in hepatocellular carcinoma and regulates cell proliferation, apoptosis, and invasion via sponging miR-548p.
    Zhang J; Chang Y; Xu L; Qin L
    J Cell Biochem; 2019 Jun; 120(6):9487-9494. PubMed ID: 30556306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linc01559 Served as a Potential Oncogene and Promoted Resistance of Hepatocellular Carcinoma to Oxaliplatin by Directly Sponging miR-6783-3p.
    Dong S; Fu Y; Yang K; Zhang X; Miao R; Long Y; Liu C
    Anticancer Agents Med Chem; 2021; 21(2):278-286. PubMed ID: 32698745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
    Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
    Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA hsa_circ_0001368 suppresses the progression of gastric cancer by regulating miR-6506-5p/FOXO3 axis.
    Lu J; Zhang PY; Li P; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Huang CM; Zheng CH
    Biochem Biophys Res Commun; 2019 Apr; 512(1):29-33. PubMed ID: 30853185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircRNA circ-0038718 promotes hepatocellular carcinoma progression through sponging miR-139-3p.
    Sun R; Li H; Li J; Shen S; Cui G; Dong G
    Biochem Biophys Res Commun; 2020 Dec; 533(4):845-852. PubMed ID: 33008587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.